Insider Trading April 6, 2026

Lands’ End Director Disposes of $156,690 in Shares Amid Tender Offer

Director Josephine Linden sells 3,482 shares at $45 per share; company posts Q4 fiscal 2025 results that miss estimates and authorizes $100M buyback program

By Jordan Park LE
Lands’ End Director Disposes of $156,690 in Shares Amid Tender Offer
LE

Josephine Linden, a director of Lands’ End, Inc. (NASDAQ: LE), sold 3,482 shares on April 1, 2026 at $45.00 per share, for total proceeds of $156,690, according to a Form 4 filed with the Securities and Exchange Commission. The transaction was executed under a $45-per-share tender offer by LEWHP, LLC, an indirect wholly owned subsidiary of WH Topco, L.P. The tender price represents a substantial premium to Lands’ End’s current share price of $10.90. Separately, the company reported fourth-quarter fiscal 2025 results that missed analysts’ expectations and authorized a share repurchase program of up to $100 million through March 31, 2029.

Key Points

  • Director Josephine Linden sold 3,482 Lands’ End shares on April 1, 2026 at $45.00 per share, generating $156,690 in proceeds.
  • The sale was part of a $45.00-per-share tender offer by LEWHP, LLC to acquire up to 2,222,222 outstanding shares; $45.00 is a significant premium to the $10.90 trading price.
  • Lands’ End reported Q4 fiscal 2025 EPS of $0.76 (miss vs $0.79 estimate) and revenue of $462.4 million (miss vs $472.24 million), while the Board authorized a $100 million buyback program through March 31, 2029.

Josephine Linden, who serves on the board of Lands’ End, Inc. (NASDAQ: LE), sold 3,482 shares of the company’s common stock on April 1, 2026, a transaction disclosed in a Form 4 filing with the Securities and Exchange Commission. The shares were transacted at $45.00 each, producing gross proceeds of $156,690.

The sale occurred in connection with a tender offer initiated by LEWHP, LLC, a wholly owned indirect subsidiary of WH Topco, L.P., which has proposed to purchase up to 2,222,222 outstanding shares of Lands’ End common stock for cash at a price of $45.00 per share. That offer price represents a significant premium to Lands’ End’s current traded price of $10.90, a figure that InvestingPro analysis indicates is below the company’s Fair Value.

Following the reported sale, Linden retains direct ownership of 42,335 shares of Lands’ End. The Form 4 that disclosed the transaction was submitted to the SEC and signed on April 6, 2026 by Peter L. Gray, acting as Attorney-in-Fact for Josephine Linden.

Market commentary included with InvestingPro Tips noted that Lands’ End’s stock has weakened over recent months, with a six-month price return of -26% and notable declines over the past three months. Those price movements were reported alongside the Lindens’ transaction details in public filings.

In a separate update, Lands’ End released fourth-quarter results for fiscal 2025 that fell short of analysts’ forecasts. The company reported earnings per share of $0.76, missing the consensus estimate of $0.79, while quarterly revenue came in at $462.4 million versus expectations of $472.24 million. The company did report a 5% increase in total revenue compared with the same quarter a year earlier.

Also disclosed by the company is a Board-authorized share repurchase program of up to $100 million of common stock, effective through March 31, 2029. The company indicated it may carry out repurchases via open market transactions, privately negotiated purchases, or other methods permitted under federal securities laws. Company statements framed these moves as part of ongoing efforts to manage financial resources and shareholder value.


All transaction details above are drawn from the company’s SEC Form 4 filing and the company’s reported quarterly results; no additional claims or projections are included beyond those public disclosures.

Risks

  • The company’s recent quarterly results missed analyst expectations for both EPS and revenue, which may weigh on investor sentiment - impacts equity markets and retail sector valuations.
  • A material gap exists between the $45.00 tender offer price and the current trading price of $10.90; the disparity highlights uncertainty about near-term liquidity and valuation - impacts shareholders and potential acquirers.
  • The company’s share price has declined markedly over six months (six-month return -26%), reflecting recent market weakness that could affect investor confidence and access to capital - impacts equity investors and related financial markets.

More from Insider Trading

Lipocine Director Purchases 123,000 Shares Amid Mixed Clinical News Apr 6, 2026 Kinder Morgan Vice President Disposes of $203K in Class P Shares Apr 6, 2026 RA Capital Disposes $14.5M of Vor Biopharma Stock Across Early April Trades Apr 6, 2026 Magnetar Financial Disposes of 23,088 Wheeler Real Estate Shares for About $21.5k Apr 6, 2026 Lipocine CEO Mahesh Patel Buys $50,749 of Stock as Company Reports Phase 3 Setback Apr 6, 2026